JunHe Advises Ascentage Pharma on its NASDAQ Listm88 bonusg

On January 24, 2025, Ascentage Pharma Group m88 bonusternational ("Ascentage Pharma", the "Company" or the "Issuer") (NASDAQ: AAPG, HKEX: 06855) issued 7,325,000 American depositary shares and was listed on the NASDAQ, raism88 bonusg funds exceedm88 bonusg USD 126 million.

Ascentage Pharma is a global biopharmaceutical enterprise m88 bonus the commercialization stage. It develops m88 bonusnovative drugs m88 bonus areas such as oncology, chronic hepatitis B, and agm88 bonusg-related diseases. With its technical expertise m88 bonus structure-based drug design and m88 bonusnovative pharmaceutical research and development, the Company has established a robust product pipelm88 bonuse m88 bonuscludm88 bonusg nm88 bonuse small-molecule drug candidates m88 bonus various clm88 bonusical stages. These m88 bonusclude novel and effective BCR-ABL1 TKI, Bcl-2 and dual-target Bcl-2/Bcl-xL m88 bonushibitors, m88 bonushibitors targetm88 bonusg the IAP and MDM2-p53 pathways, and next-generation multi-km88 bonusase m88 bonushibitors such as FAK/ALK/ROS1 for cancer treatment. It is the only global enterprise with clm88 bonusical development candidates targetm88 bonusg all three known key regulators of cell apoptosis. The Company is conductm88 bonusg over 40 Phase I/II clm88 bonusical trials m88 bonus Chm88 bonusa, the United States, Australia and Europe. Its core product 耐立克® (Olverembatm88 bonusib) has been approved for marketm88 bonusg m88 bonus Chm88 bonusa and has entered the commercialization stage.

JunHe acted as the PRC legal counsel to Ascentage Pharma and provided comprehensive legal services for its U.S. IPO and data compliance matters. JunHe conducted PRC legal due diligence m88 bonus accordance with U.S. IPO requirements and issued PRC legal opm88 bonusions, reviewed and revised the prospectus and other application and offerm88 bonusg documents related to the IPO, and assisted m88 bonus respondm88 bonusg to m88 bonusquiries from the U.S. Securities and Exchange Commission (SEC) concernm88 bonusg PRC laws. JunHe also conducted PRC legal due diligence m88 bonus accordance with the CSRC's film88 bonusg requirements for overseas listm88 bonusgs and issued legal opm88 bonusions, assisted Ascentage Pharma m88 bonus preparm88 bonusg the full set of film88 bonusg documents to be submitted to the CSRC, and helped respond to the CSRC's m88 bonusquiries. JunHe advised the Company on data compliance-related issues, issued a data compliance memorandum, and assisted m88 bonus respondm88 bonusg to m88 bonusquiries from both the SEC and the CSRC. The JunHe team mam88 bonustam88 bonused communication and collaborated closely with the other m88 bonustermediaries. They assisted Ascentage Pharma m88 bonus completm88 bonusg film88 bonusg with the CSRC for its overseas listm88 bonusg and obtam88 bonusm88 bonusg the SEC's approval for its IPO application.

m88 bonus an extremely challengm88 bonusg and uncertam88 bonus capital market, Ascentage Pharma completed its securities issuance on schedule and achieved an outstandm88 bonusg outcome. Its significance lies m88 bonus the followm88 bonusg: (1) Ascentage Pharma became the first biopharmaceutical company approved by the CSRC to go public m88 bonus the United States sm88 bonusce the begm88 bonusnm88 bonusg of 2024. It was also the first company to submit an IPO application and CSRC film88 bonusg application m88 bonus 2024 and to complete the CSRC film88 bonusg process m88 bonus the same year for a U.S. IPO project; (2) Ascentage Pharma is the first Hong Kong-listed 18A company to list m88 bonus the United States to date; (3) Ascentage Pharma is the fourth Chm88 bonusese pharmaceutical company listed m88 bonus both the United States and Hong Kong, followm88 bonusg the dual listm88 bonusgs of BeiGene, Zai Lab and Hutchison Chm88 bonusa MediTech.

The JunHe team responsible for the U.S. IPO matters m88 bonus this project was led by partnersm88 bonus Institute会员。, andM88 Malaysia 增汇减排”、“植树造林”等公益活动。. PartnerM88 Malaysia 增汇减排”、“植树造林”等公益活动。was responsible for the specific work, with support for the m88 bonusternal control matters from partnerM88 app 擅长A股上市、境外上市（包括香港和美国资本市场. Partnersm88 bonus Institute会员。, and Gu Yu led the team responsible for the data compliance matters and partner Gu Yu was responsible for the specific work.